Dual Remission in Patients with Moderate-to-Severe Asthma and CRSwNP Treated with Dupilumab: A 24-Month Real-World Study
Dupilumab is highly effective, enabling 88% of patients to achieve Dual Remission after 24 months. However, full olfactory restitution is distinct from structural polyp regression and harder to achieve, likely due to persistent neuroepithelial damage.
Authors
- Alvise Berti (ORCID: https://orcid.org/0000-0002-7831-921X)
- Walter Cestaro (ORCID: https://orcid.org/0000-0002-3612-1440)
- Francesco Menzella (ORCID: https://orcid.org/0000-0003-3950-5789)
- F Gialdini
- Annamaria Bosi
- Tatiana Scandiuzzi Piovesan (ORCID: https://orcid.org/0009-0009-7080-0859)
- Sara Munari (ORCID: https://orcid.org/0000-0003-1024-2997)
- Eugenio De Corso
- Marcello Cottini
- Lorenzo Corsi
- Carlo Lombardi
Institutions
- University of Bergamo (IT)
- University of Trento (IT)
- University of Perugia (IT)
- Ospedale Santa Chiara (IT)
- AULSS 2 Marca Trevigiana (IT)
- Presidio Ospedaliero (IT)
- Fondazione Poliambulanza Istituto Ospedaliero (IT)
Publication Details
- Journal
- Journal of Clinical Medicine
- Published
- 2026-04-07
- DOI
- https://doi.org/10.3390/jcm15072787
- Primary Topic
- Sinusitis and nasal conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00